| Identification | Back Directory | [Name]
CORTISTATIN-14 | [CAS]
186901-48-4 | [Synonyms]
CST-14
CST-14 (RAT)
13)-disulfide
CORTISTATIN-14
CORTISTATIN (RAT)
CORTISTATIN (16-29)
Cortistatin-14(mouse)
Cortistatin14,Cortista
CORTISTATIN-14 USP/EP/BP
Cortistatin 14, human, rat
Cortistatin 14, ≥97% (HPLC)
CORTISTATIN-14 (MOUSE, RAT)
M.W. 1721.04 C81H113N19O19S2
(DES-ALA1,PRO2,SER12)-SOMATOSTATIN-14-LYS
PRO-CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-SER-SER-CYS-LYS
H-PRO-CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-SER-SER-CYS-LYS-OH
2-L-Proline-14a-L-lysinamide-2-14-somatostatin (Petromyzon marinus)
Cortistatin-14 (Mouse, rat)
(Des-Ala1,Pro2,Ser12)-SoMatostatin-14-Lys
Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys [Disulfide bridge: 2–13]
PRO-CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-SER-SER-CYS-LYS(DISULFIDE BRIDGE:CYS2-CYS13)
CST-14, Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys [Disulfide bridge: 2-13]
PRO-CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-SER-SER-CYS-LYS: PCKNFFWKTFSSCKDISULFIDE BRIDGE CYS2-CYS13
L-LysinaMide,L-prolyl-L-cysteinyl-L-lysyl-L-asparaginyl-L-phenylalanyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-cysteinyl-,cyclic (2®
L-Lysinamide, L-prolyl-L-cysteinyl-L-lysyl-L-asparaginyl-L-phenylalanyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-L-seryl-L-seryl-L-cysteinyl-, cyclic (2→13)-disulfide | [Molecular Formula]
C81H114N20O18S2 | [MDL Number]
MFCD01075120 | [MOL File]
186901-48-4.mol | [Molecular Weight]
1720.03 |
| Chemical Properties | Back Directory | [Boiling point ]
2012.6±65.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
1% acetic acid: 1mg/mL, clear, colorless | [form ]
Solid | [pka]
12.47±0.70(Predicted) | [color ]
White to off-white | [Sequence]
{Pro}{Cys}{Lys}{Asn}{Phe}{Phe}{Trp}{Lys}{Thr}{Phe}{Ser}{Ser}{Cys}{Lys}-NH2 (Disulfide bridge: Cys2-Cys13) | [InChIKey]
DDRPLNQJNRBRNY-WYYADCIBSA-N |
| Hazard Information | Back Directory | [Uses]
Cortistatin-14 may be used in competition binding assay with sst4 receptors (CHO-sst4) of CHO cells and sst1 receptors (CHO-sst1). | [Biological Activity]
Cortistatin-14like somatostatin inhibits the physiological activity of hippocampal neurons. It binds and exerts its function through all the somatostatin receptors (sst1-sst5). It shows anticonvulsive and neuroprotective effect. Cortistatin-14 has remarkable anti-inflammatory properties.''Somatostatin-like neuropeptide with neuronal depressant and sleep modulating properties. Exogenous cortistatin impairs short-term memory processing. | [in vivo]
Cortistatin-14 (10-250 μg/kg; injected in the footpad or intraperitoneal injection; six times a day) reduces acute neurogenic plasma protein leakage in the hind paw skin of rats caused by mustard oil, as well as carrageenan-induced paw edema in mice, mechanical hyperalgesia, the production of IL-1β and tumor necrosis factor-α, and mild heat injury-induced thermal hyperalgesia[1].
Cortistatin-14 (10 μg; intravenous injection; single dose) plays a regulatory role in the pituitary secretion of male rats[2].
Cortistatin-14 (1-10 nM, intracerebroventricular injection; single dose) has anticonvulsant and neuroprotective effects in rats by binding to somatostatin receptors, which leads to a reduction in the release of excitatory neurotransmitters[3]. | Animal Model: | Hydrochloride-induced rat[3] | | Dosage: | 1 and 10 nM; single dose | | Administration: | Intracerebroventricular injection (ICV) | | Result: | Relieved epilepsy, inhibited neuronal loss, prevented the reduction of immune-active somatostatin and its receptors in the hippocampus, and reduced the release of 3H-D-aspartate under stimulation. |
| Animal Model: | Endotoxin-stimulated mice[1] | | Dosage: | 10 μg/kg (i.p.); 100 μg/kg (i.p.); 250 μg/kg (i.pl.); six times a day | | Administration: | Intraperitoneal injection (i.p.); i.pl. | | Result: | Reduced the concentrations of TNF-α and IL-1β, reduced mustard oil-induced plasma protein extravasation in the dorsal skin, with an inhibition rate of nearly 80%, inhibited plantar thermal hyperalgesia in rats caused by mild thermal injury (51°C, 20 seconds). |
| Animal Model: | Wistar-Kyoto rat[2] | | Dosage: | 10 μg; single dose | | Administration: | Intravenous injection (i.v.) | | Result: | Reduced growth hormone concentrations without affecting LH and FSH concentrations. |
| [IC 50]
SSTR1; SSTR2; SSTR3; SSTR4; SSTR5 |
|
|